Literature DB >> 10534175

Clinical significance of genetic imbalances revealed by comparative genomic hybridization in chondrosarcomas.

M L Larramendy1, N Mandahl, F Mertens, C Blomqvist, A H Kivioja, E Karaharju, J Valle, T Böhling, M Tarkkanen, A Rydholm, M Akerman, H C Bauer, J P Anttila, I Elomaa, S Knuutila.   

Abstract

DNA copy number changes were studied by comparative genomic hybridization (CGH) in 50 chondrosarcoma samples from 45 patients. Mean number of genetic aberrations in primary tumors was 4.8 +/- 1.8. The most frequently gained regions were 20q12-qter (37%), 20q (32%), 8q24.1-qter (27%), 20p (24%), and 14q24-qter (24%). Losses were 5.5 times less frequent than gains and observed mainly at Xcen-q21, 6cen-q22, and 18cen-q11.2 (11% each). Recurrent and metastatic tumors showed a mean of 4.0 +/- 2.2 aberrations per sample. The most frequently gained regions were chromosome 7 (4 cases), 5q14-q32 (4 cases), 6p (3 cases), and 12q (3 cases). Losses of DNA sequences were 3.4 times less frequent than gains. Histological tumor grade was significantly associated with metastasis-free survival (P = .002) and overall survival (P = .003), being the strongest prognostic factor tested. A statistically significant correlation was found between gain at 8q24.1-qter and shorter overall survival (P = .01) but not with local recurrence or metastasis-free survival. Gain at 14q24-qter was associated with a trend to shorter overall survival (P = .05) but neither with an increased risk for local recurrence nor with metastasis-free survival. In a multivariate analysis, only the tumor grade associated with overall survival (P = .02). In a multivariate analysis together with the tumor grade, gain at 8q24.1-qter did not retain its significance (P = .44), indicating that this imbalance is not an independent prognostic factor.

Entities:  

Mesh:

Year:  1999        PMID: 10534175     DOI: 10.1016/s0046-8177(99)90045-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  Chondrosarcomatous differentiation in diffuse-type gastric carcinoma.

Authors:  Vincenzo Villanacci; Marco Gambarotti; Alessandro Ubiali; Giancarlo Cervi; Giuseppe Pulcini; Vittorio De Cesare; Gabrio Bassotti
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 2.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 3.  Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Authors:  Federica Recine; Alberto Bongiovanni; Nada Riva; Valentina Fausti; Alessandro De Vita; Laura Mercatali; Chiara Liverani; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2017-02-23       Impact factor: 4.147

4.  Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation.

Authors:  Naoko Kudo; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Wenguang Gu; Hajime Umezu; Tsuyoshi Toyama; Naoto Endo
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.